South Korea has emerged as one of the strategic location for the development of biosimilars on the global level. Among the various emerging countries identified for development of biosimilars, South Korea is one of the most promising countries where pharmaceutical companies have identified huge investment potentials for the drug development process. One of the major reasons for the attractiveness of South Korea is the end of patent protection for some blockbuster drugs in the coming years and the need for novel therapeutics. Offering the advantages of favorable government and business conducive environment, the South Korean biosimilars market is poised for significant and rapid growth in the future years. There are many favorable steps undertaken by the government in this regard, some of them being tax holidays, tax concessions, cash grant, site location support and financial support for pharmaceutical companies investing in Korea.
Thus, with all the government policies and frameworks, the biosimilars market in South Korea has become the growth engine of the country attracting huge investments from public and private companies located in and outside Korea. The South Korean Government has announced its plans to promote the biosimilars industry and make huge investments in the industry so as to make Korea a dominant player in the global marketplace.
At present, the share of South Korea in the global biosimilars development is extremely meager. However, with the aggressive government support, and the increasing focus on biosimilars development, the government aims that the country would occupy a significant share of the global market for biosimilars by 2020.
“South Korea Biosimilar Market Analysis” reports gives comprehensive details on following aspects related to Biosimilar development in South Korea:
Market Overview Favorable Market Parameters Biosimilar Pipeline Analysis by Company, Phase & Disease Regulation foe Development of Biosimilars Emerging Market Trends Competitive Landscape Agreement & Partnership for Development of Biosimilars
Our reports have been used by over 10K customers, including:
175 pages •
By The Business Research Company
• Apr 2021
Major players in the oral biologics and biosimilar market are Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma, Entera Bio Ltd. and Allergan plc. The global oral biologics & biosimilar drugs market is expected to grow from $3.53 billion in 2020 to...
The Global Biosimilars Partnering Terms and Agreements 2010 to 2021 report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Biosimilars partnering deals Disclosed headlines, upfronts, milestones and royalties...
The biosimilar market reached a value of US$ 7.7 Billion in 2020. This market is currently being driven by a number of factors such as patent expires of blockbuster biological drugs, lower prices, rising prevalence of chronic diseases, and cost-saving initiatives from governments and third-party payers. Catalyzed by these factors, the market...
200 pages •
By The Business Research Company
• Dec 2020
Major players in the pegfilgrastim biosimilars market are Mylan, Biocon, Mundipharma, Pfizer, Sandoz, Coherus, Intas Pharmaceuticals and Fresenius Kabi. The global pegfilgrastim biosimilar market is expected to decline from $534.43 million in 2019 to $453.11 million in 2020 at a compound annual growth rate (CAGR) of -15.22%. The decline...
In this research service, the Transformational Health team provides critical insights into the global biosimilar industry, highlighting the key growth opportunities, market revenue forecasts, and trends that will influence the industry with the emergence of the third wave of biosimilars. The global third-wave biosimilars market covered in...
Since 2009, 25 biosimilars of 12 originator products are approved in Japan and have yielded mixed performances and attained annual sales of ~¥32.4b ($300m). Unique biosimilars landscape with the entry of NESP “biosame” by originator Kyowa Hakko Kirin through its subsidiary, co-promotion/marketing collaboration with local companies for the...
Competitor Landscape: Spondyloarthritis Summary "Competitor Landscape: Spondyloarthritis", briefings contain evaluations of ongoing development activities within the Spondyloarthritis (SpA) disease market, together with analysis of current & potential future product positioning. Key Highlights...
Summary SK Biopharmaceuticals Co Ltd (SK Biopharmaceuticals), a subsidiary of SK Holdings Co Ltd is a researcher and developer of drugs.The company develops and markets drugs for the treatment of central nervous system. It provides plumiaz, SKL-N05 and JZP-110; YKP3089, relenopride, SKL-PD, SKL-A4R, SKL-PSY and FZ-016;...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.